Cécile Bétry

Dr. Cécile Bétry

Department of Endocrinology, Diabetology, Nutrition, CHU Grenoble Alpes, Grenoble, France
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
APAlan L. Pehrson
Alan L. Pehrson
TCThomas Cremers
Thomas Cremers
Cécile BétryCécile Bétry
Cécile Bétry
MHMarieke G.C. van der Hart
Marieke G.C. van der Hart
LJLaerke Jørgensen
Laerke Jørgensen
CSConnie Sanchez
Connie Sanchez

1 June 2015 in Diabetes & Metabolism
Verified
Journal Article
Closed access
Cécile BétryCécile Bétry
Cécile Bétry
MCM.A. Challan-Belval
M.A. Challan-Belval
ABA. Bernard
A. Bernard
ACA. Charrié
A. Charrié
JDJ. Drai
J. Drai
EDEmmanuel Disse
Emmanuel Disse

7 April 2011 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Cécile BétryCécile Bétry
Cécile Bétry
AEAdeline Etievant
Adeline Etievant
COChris Oosterhof
Chris Oosterhof
BEBjarke Ebert
Bjarke Ebert
CSConnie Sanchez
Connie Sanchez
NHNasser Haddjeri
Nasser Haddjeri
Serotonin (5-HT)3 receptors are the only ligand-gated ion channel of the 5-HT receptors family. They are present both in the peripheral and central nervous system and are localized in several areas involved in mood regulation (e.g., hippocampus or prefrontal cortex). Moreover, they are involved in regulation of neurotransmitter systems implicated in the pathophysiology of major depression (e.g., dopamine or GABA). Clinical and preclinical studies have suggested that 5-HT3 receptors may be a relevant target in the treatment of affective disorders. 5-HT3 receptor agonists seem to counteract the effects of antidepressants in non-clinical models, whereas 5-HT3 receptor antagonists, such as ondansetron, present antidepressant-like activities. In addition, several antidepressants, such as mirtazapine, also target 5-HT3 receptors. In this review, we will report major advances in the research of 5-HT3 receptor’s roles in neuropsychiatric disorders, with special emphasis on mood and anxiety disorders.

1 August 2015 in EBioMedicine
Verified
Journal Article
Open access
AEA. Etiévant
A. Etiévant
COC. Oosterhof
C. Oosterhof
Cécile BétryCécile Bétry
Cécile Bétry
EAE. Abrial
E. Abrial
MNM. Novo-Perez
M. Novo-Perez
NHNasser Haddjeri
Nasser Haddjeri
Although deep brain stimulation (DBS) shows promising efficacy as a therapy for intractable depression, the neurobiological bases underlying its therapeutic action remain largely unknown. The present study was aimed at characterizing the effects of infralimbic prefrontal cortex (IL-PFC) DBS on several pre-clinical markers of the antidepressant-like response and at investigating putative non-neuronal mechanism underlying DBS action. We found that DBS induced an antidepressant-like response that was prevented by IL-PFC neuronal lesion and by adenosine A1 receptor antagonists including caffeine. Moreover, high frequency DBS induced a rapid increase of hippocampal mitosis and reversed the effects of stress on hippocampal synaptic metaplasticity. In addition, DBS increased spontaneous IL-PFC low-frequency oscillations and both raphe 5-HT firing activity and synaptogenesis. Unambiguously, a local glial lesion counteracted all these neurobiological effects of DBS. Further in vivo electrophysiological results revealed that this astrocytic modulation of DBS involved adenosine A1 receptors and K(+) buffering system. Finally, a glial lesion within the site of stimulation failed to counteract the beneficial effects of low frequency (30 Hz) DBS. It is proposed that an unaltered neuronal-glial system constitutes a major prerequisite to optimize antidepressant DBS efficacy. It is also suggested that decreasing frequency could heighten antidepressant response of partial responders.

29 February 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
DMDiego Mastino
Diego Mastino
MRMaud Robert
Maud Robert
Cécile BétryCécile Bétry
Cécile Bétry
MLMartine Laville
Martine Laville
CGChristian Gouillat
Christian Gouillat
EDEmmanuel DISSE
Emmanuel DISSE

1 June 2013 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
Cécile BétryCécile Bétry
Cécile Bétry
APAlan L. Pehrson
Alan L. Pehrson
AEAdeline Etiévant
Adeline Etiévant
BEBjarke Ebert
Bjarke Ebert
CSConnie Sánchez
Connie Sánchez
NHNasser Haddjeri
Nasser Haddjeri
The therapeutic effect of current antidepressant drugs appears after several weeks of treatment and a significant number of patients do not respond to treatment. Here, we report the effects of the multi-modal antidepressant vortioxetine (Lu AA21004), a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and 5-HT transporter (SERT) inhibitor, on rat 5-HT neurotransmission. Using in vivo electrophysiological recordings in the dorsal raphe nucleus of anaesthetized rats, we assessed the acute and subchronic effects of vortioxetine and/or the selective 5-HT3 receptor agonist, SR57227 or the selective 5-HT1A receptor agonist flesinoxan, on 5-HT neuronal firing activity. Using ex-vivo autoradiography, we correlated SERT occupancy and presumed 5-HT firing activity. The selective serotonin reuptake inhibitor, fluoxetine, was used as comparator. Importantly, the recovery of 5-HT neuronal firing was achieved after 1 d with vortioxetine and 14 d with fluoxetine. SR57227 delayed this recovery. In contrast, vortioxetine failed to alter the reducing action of 3 d treatment of flesinoxan. Acute dosing of vortioxetine inhibited neuronal firing activity more potently than fluoxetine. SR57227 prevented the suppressant effect of vortioxetine, but not of fluoxetine. In contrast, flesinoxan failed to modify the suppressant effect of vortioxetine acutely administered. Differently to fluoxetine, vortioxetine suppressed neuronal firing without saturating occupancy at the SERT. Vortioxetine produced a markedly faster recovery of 5-HT neuronal firing than fluoxetine. This is at least partly due to 5-HT3 receptor antagonism of vortioxetine in association with its reduced SERT occupancy.